Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386208 | 0.79 | CA1 (0.34) | LMNAALDH1A1 | |
| SCHEMBL6923614 | 0.75 | SHBG (0.36) | KDM4EL3MBTL1HSPA5CYP2C9CYP2C19 | |
| SCHEMBL17429682 | 0.73 | FFAR4 (0.36) | KDM4EL3MBTL1HSPA5CYP2C9CYP2C19 | |
| SCHEMBL3593411 | 0.73 | GABRA1 (0.41) | KDM4EL3MBTL1HSPA5CYP2C9CYP2C19 | |
| SCHEMBL6243403 | 0.73 | KDM4E (0.38) | KDM4EL3MBTL1HSPA5SMN1; SMN2LMNA | |
| SCHEMBL2290449 | 0.73 | ALDH1A1 (0.33) | KDM4EL3MBTL1HSPA5CYP2C9CYP2C19 | |
| SCHEMBL3023153 | 0.72 | TP53 (0.41) | KDM4EL3MBTL1CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL156826 | 0.68 | RAPGEF4 (0.45) | KDM4EHSD17B10LMNAALDH1A1 | |
| SCHEMBL9747633 | 0.68 | ALDH1A1 (0.39) | KDM4EL3MBTL1HSPA5CYP2C9CYP2C19 | |
| SCHEMBL15262985 | 0.67 | MAPT (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | KDM4E 3682/4885L3MBTL1 4322/4885HSPA5 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.